

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

361 M

Board of Directors

Dr Graham Kelly
Chairman &
Executive Director

Steve Coffey
Non Executive Director

John O'Connor
Non Executive Director

Prof Peter Gunning
Non Executive Director

ASX RELEASE
18 May 2015

NOVOGEN TO PRESENT AT HONG KONG INVESTOR CONFERENCE

May 18 2015, Sydney, Australia: US-Australian drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that company CEO, Dr Graham Kelly, will be a presenting company at Asia Biotech Invest 2015 May 20-21.

The Novogen presentation is at 10.00 am May 20 at the Sheraton Hotel and Towers, Hong Kong.

The event is co-delivered by AusBiotech and Beacon Events, and supported by partners including ChinaBio Group, HKBio, ASX and Austrade.

Information about the program, speaker line up and spotlight company presentations is available at www.asiabiotechinvest.com

Novogen CEO, Graham Kelly, said, "This week represents our inaugural exposure of the Company to the Asian investment market. A review of our share registry has revealed a growing and significant level of shareholding out of Asia, so the conference presents a timely opportunity to start highlighting the Novogen story to this enormous investment market. The conference presentation will be accompanied by a road-show to institutional investors in Hong Kong. With our need for funds well on the way to being satisfied, it is now a case of highlighting the investment opportunity by on-market buying in the Company's two first-in-class technology platforms."

About Novogen

Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of preventing tumor recurrence. This objective is based on a strategy of achieving comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical debulking effect on their daughter cells.

For more information, please visit www.novogen.com



Corporate Contact

Dr. Graham Kelly
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4101

Media Enquiries

Prue Kelly
Media Officer
Novogen Group
Prue.Kelly@novogen.com
+61 (0) 2 9472 4101

